论文部分内容阅读
新的二萜醇紫杉醇(taxol)(1)成为最重要的前导化合物之一是近几年筛选天然产物的结果。1971年Wall等首先分离到(1),它显示对抗Walker 256癌肉瘤、肉瘤180及Lewis氏肺癌等多种白血病有效的活性。紫杉醇临床结果非常鼓舞人心,尽管第一期试验存在着一些问题。从第Ⅱ期临床试验的结果显示紫杉醇有极好的抗卵巢癌活性。紫杉醇有限的供给阻止外延临床研究,但作为一个临床有效的抗癌剂是有光明前途的。曾有报道从简单的二萜醇浆果紫杉亭Ⅲ
New diterpene taxol (1) One of the most important leading compounds is the result of the screening of natural products in recent years. In 1971, Wall et al. (1) were first isolated and showed potent activity against a variety of leukemias, such as Walker 256 Carcinoma, Sarcoma 180 and Lewis Lung Cancer. The clinical results of paclitaxel are very encouraging, although there are some problems with the first phase of the trial. Results from Phase II clinical trials show that paclitaxel has excellent anti-ovarian cancer activity. The limited availability of paclitaxel prevents the clinical study of epigenesis, but there is a bright future as a clinically effective anticancer agent. There have been reports from the simple diterpene alcoholic berry yew Pavilion III